| Literature DB >> 26273830 |
Ehtesham Iqbal1, Robbie Mallah2, Richard George Jackson3, Michael Ball3, Zina M Ibrahim1, Matthew Broadbent4, Olubanke Dzahini2, Robert Stewart3, Caroline Johnston1, Richard J B Dobson5.
Abstract
OBJECTIVES: Electronic healthcare records (EHRs) are a rich source of information, with huge potential for secondary research use. The aim of this study was to develop an application to identify instances of Adverse Drug Events (ADEs) from free text psychiatric EHRs.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26273830 PMCID: PMC4537312 DOI: 10.1371/journal.pone.0134208
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Remove and Retain rules.
Flow diagram representing the use of the Remove and Retain rules to identify ADE instances.
Examples of rule firing annotations.
Rules were deployed within the JAPE of GATE.
| Text where Removal rules are used | Text where Retain rules are used |
|---|---|
| ‘ext where | ‘ave dystoniatain |
| ‘dyston | ‘any dystonic re |
| ‘dystonia had bec | ‘of dystonia w |
| ‘dystonia was | ‘have always been a useful resou |
| ‘ | |
| ‘ | |
| ‘any dyst |
Fig 2Iterative ADE tool development process.
Flow diagram showing the iterative approach taken in development of the tool.
Corresponding precision and recall by applying each set of JAPE rules on dystonia corpus.
| Stage | JAPE Rule | Purpose of rule | Precision | Recall |
|---|---|---|---|---|
| Keyword Search only | Baseline estimates. Not used in iteration process. | 62% | 98% | |
| 1 | Negation Before ADE terms | This rule negates the ADE terms which appear before the negation terms. The terms are present in the ‘negationbefore’ gazetteer. | 71% | 65% |
| 2 | Negation After ADE terms | This rule negates the ADE terms which appear after the negation terms. The terms are present in the ‘negationafter’ gazetteer. | 73% | 68% |
| 3 | Organisation | This rule negates the ADE terms appear before or after organisation terms (i.e. dystonia workshop). The terms are present in the ‘organisation’ gazetteer. | 74% | 68% |
| 4 | Symbols and punctuations | These rules negate the ADE terms if symbols and punctuations (like; ‘?’, ‘/’ and ‘@’) appear before or after the ADE terms, with or without any space tokens. | 76% | 70% |
| 5 | Other Person | This rule negates the of ADE terms if other person is discussed in the sentence. The terms are present in the ‘people’ gazetteer. | 77% | 70% |
| 6 | Monitor | These 2 rules negate the ADE terms if clinicians are monitoring for ADE. The terms are present in the ‘monitor’ gazetteer. | 78% | 73% |
| 7 | Negative effects | These 7 rules negate the ADE terms where clinicians are explaining, informing, potential and common ADE to the patient. The negative effects terms are present in ‘negseffect’ gazetteer. | 79% | 76% |
| 8 | Single words around ADE | These 2 rules negates the ADE terms where words appears before the ADE (i.e. ‘like’, ‘rates’) and after the ADE (i.e. ‘consider’) | 80% | 78% |
| 9 | Diagnosis | This rule negate the ADE terms which are actually the diagnosis (i.e. ego dystonia) The terms are present in the ‘diagnost’ gazetteer. | 83% | 80% |
| 10 | Drugs Effects / Vaccine | These 6 rules negate the ADE terms where clinicians are discussing/explaining the side effects of a drug. The side effects terms are present in the ‘druglink’ gazetteer. | 87% | 82% |
| 11 | If statement | These 2 rules negate the ADE terms which are hypothetically discussed as a reaction/indication. The ADE indication terms are present in ‘ADRin’ gazetteer. | 89% | 85% |
| 12 | Retain Rule | These 3 rules un-negate the negation if ADEs terms are present within close proximity of patient name and ADE indication terms present in ‘ADRin’ gazetteer. | 93% | 89% |
Fig 3Precision and recall plot for dystonia JAPE rule development.
The plot shows the evolution of the performance over the iterative JAPE rule development process for dystonia.
Performance metrics for JAPE rules identifying extrapyramidal side-effects (EPSEs).
| EPSE | Precision | Recall | ||
|---|---|---|---|---|
| Using keyword search only | With Remove and Retain rules applied | Using keyword search only | With Remove and Retain rules applied | |
| Dystonia | 0.62 | 0.93 | 0.98 | 0.89 |
| Akathisia | 0.61 | 0.92 | >0.99 | 0.86 |
| Parkinsonism | 0.58 | 0.85 | 0.94 | 0.88 |
| Tardive dyskinesia | 0.89 | 0.97 | >0.99 | 0.90 |
Recorded EPSE frequencies for patients with serious mental illness (SMI) according to demographic status and diagnosis.
The numbers reflect a cohort of 12879 patients from 2007 to 2013.
| EPSE | Dystonia | Akathisia | Parkinsonism | Tardive Dyskinesia | |
|---|---|---|---|---|---|
| Total Number of Patients | 390 | 750 | 440 | 324 | |
|
|
|
| |||
| Under 21 | 318 | 5.97% | 8.18% | 3.46% | 0.63% |
| 21 to 30 | 2106 | 4.51% | 6.03% | 2.71% | 1.47% |
| 31 to 40 | 3018 | 3.61% | 5.40% | 2.78% | 1.46% |
| 41 to 50 | 3249 | 2.65% | 6.25% | 2.22% | 2.28% |
| 51 to 60 | 2119 | 2.27% | 5.85% | 3.21% | 2.41% |
| 61 to 70 | 1129 | 1.86% | 5.93% | 6.20% | 5.23% |
| 71 to 80 | 677 | 1.33% | 4.73% | 9.31% | 7.39% |
| Above 80 | 263 | 1.14% | 3.04% | 5.70% | 4.94% |
| Chi-Square value (7 df) P-Value | 49.568 <0.001 | 10.648 0.155 | 123.193 <0.001 | 10.648 <0.001 | |
|
|
|
| |||
| Male | 6969 | 3.49% | 6.50% | 3.26% | 2.55% |
| Female | 5910 | 2.49% | 5.03% | 3.60% | 2.47% |
| Chi-Square value (1 df) P-Value | 10.881 <0.001 | 12.684 <0.001 | 1.165 0.280 | 0.092 0.762 | |
|
|
|
| |||
| White | 5788 | 2.32% | 6.10% | 3.27% | 2.16% |
| Black | 4682 | 4.44% | 5.55% | 3.55% | 3.25% |
| Asians | 861 | 2.32% | 8.13% | 6.04% | 3.14% |
| Other | 1548 | 1.81% | 4.33% | 2.13% | 1.29% |
| Chi-Square value (3 df) P-Value | 51.214 <0.001 | 16.088 <0.001 | 26.332 <0.001 | 23.990 <0.001 | |
|
|
|
| |||
| Schizophreniform | 8411 | 3.11% | 5.91% | 3.40% | 2.87% |
| Bipolar | 3208 | 2.03% | 3.99% | 2.77% | 1.00% |
| Schizoaffective | 1260 | 5.00% | 9.92% | 5.16% | 4.05% |
| Chi-Square value (2 df) P-Value | 27.867 <0.001 | 58.342 <0.001 | 15.607 <0.001 | 46.399 <0.001 | |
Performance metrics for JAPE rules identifying selected other (non-EPSE) adverse drug events (ADEs).
| ADE | Precision | Recall | ||
|---|---|---|---|---|
| Using keyword search only | With Remove and Retain rules | Using keyword search only | With Remove and Retain rules | |
| Alopecia | 0.87 | 0.92 | >0.99 | 0.76 |
| Convulsions (seizures) | 0.68 | 0.88 | >0.99 | 0.81 |
| Hypersalivation (sialorrhea) | 0.91 | 0.95 | >0.99 | 0.82 |
| Myocarditis | 0.34 | 0.64 | >0.99 | 0.69 |
| Nausea | 0.68 | 0.96 | 0.96 | 0.74 |
| Pneumonia | 0.77 | 0.84 | >0.99 | 0.82 |
| Stevens-Johnson syndrome | 0.29 | 0.59 | >0.99 | 0.73 |
| Tachycardia | 0.85 | 0.93 | >0.99 | 0.83 |
Inter-annotator agreement test results.
| ADE | Agreement (%) | Cohenment (%)ator a |
|---|---|---|
| Akathisia | 88% | 0.74 |
| Alopecia | 92% | 0.70 |
| Dystonia | 96% | 0.91 |
| Myocarditis | 88% | 0.69 |
| Parkinsonian | 90% | 0.80 |